biotech / news / / Benzinga
AstraZeneca Secures FDA Approval For Baxfendy In Hypertension.
AstraZeneca won FDA approval for Baxfendy, a new aldosterone-blocking hypertension drug for resistant cases.
KEY POINTS
- Baxfendy's approval was based on Phase 3 BaxHTN trial data showing significant blood pressure reduction.
- FDA expanded Enhertu approvals to both neoadjuvant and adjuvant settings for HER2-positive early breast cancer.
- In DESTINY-Breast05, Enhertu halved the risk of disease recurrence or death compared to trastuzumab emtansine.
- AstraZeneca owes Daiichi Sankyo $155 million in milestone payments following the Enhertu approvals.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →